CancerDrs

Cervical Cancer clinical trials in Arizona

25 actively recruiting cervical cancer trials at 12 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Arizona:
  • Ironwood Cancer and Research Center — Chandler, Arizona
  • University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Arizona:
  • Research Site — Phoenix, Arizona
  • Research Site — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Arizona:
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Arizona:
  • Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
  • Arizona Center for Cancer Care-Peoria — Peoria, Arizona
  • Arizona Center for Cancer Care - Phoenix — Phoenix, Arizona
  • Arizona Center for Cancer Care - Scottsdale — Scottsdale, Arizona
  • Arizona Center for Cancer Care-Surprise — Surprise, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Arizona:
  • Phoenix Childrens Hospital — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Arizona:
  • Banner Health- MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Arizona:
  • Mayo Clinic Comprehensive Cancer Center — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…

Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Arizona:
  • Mayo Foundation for Medical Education and Research - Mayo Cl — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard tr…

Sponsor: Mayo Clinic
NCT ID: NCT05541016
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…

Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Arizona:
  • Mayo Clinic Arizona — Phoenix, Arizona
  • HonorHealth Research and Innovation Institute — Scottsdale, Arizona
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arizona:
  • Kingman Regional Medical Center — Kingman, Arizona
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…

Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Arizona:
  • HonorHealth Cancer Care - Biltmore - AZCCC Imaging — Phoenix, Arizona
  • HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy — Phoenix, Arizona
  • Sonora Quest Laboratories, LLC — Phoenix, Arizona
  • South West Medical Imaging (SMIL) — Phoenix, Arizona
  • Schwartz Laser Eye Center — Scottsdale, Arizona
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arizona:
  • Massive Bio SYNERGY-AI site — Scottsdale, Arizona
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Arizona:
  • Research Site — Bullhead City, Arizona
  • Research Site — Casa Grande, Arizona
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Cancer Genetic Testing in Ethnic Populations

This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk. The information from this s…

Sponsor: Mayo Clinic
NCT ID: NCT04475640
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07